RCS - Frontier IP Group - Amprologix raises £740,000 in Pre-Series A round

Frontier IPAnnouncement

20/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251020:nRST9181Da&default-theme=true

RNS Number : 9181D  Frontier IP Group plc  20 October 2025

REACH - a non-regulatory announcement

AIM: FIPP

20 October 2025

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Amprologix raises £740,000 in pre-Series A funding round to
accelerate development of novel antibiotics

 

Frontier IP, a specialist in commercialising intellectual property, today
notes the following announcement from portfolio company Amprologix (or the
"Company") that it has raised £740,000 to accelerate development of its novel
antibiotics to combat antimicrobial-resistant diseases.

 

The money will be used to complete pre-clinical development of the Company's
lead candidate, epidermicin NI01, in readiness for Phase I human clinical
trials in 2026. Amprologix is also positioning itself for a Series A funding
round.

 

Investors in the funding round include angel-investor network Plutus
Investment Group LLP, another institution, and individuals. Plutus Investment
Group's Venture Partner Dr Rita Dobmeyer is to join the Amprologix board as a
Non-Executive Director and will support clinical development. Global
full-service Contract Research Organisation InClin is supporting pre-clinical
and clinical development work.

 

Epidermicin NI01 is being developed to tackle Methicillin-resistant
Staphylococcus aureus (MRSA), a leading cause of healthcare-associated and
community-acquired infections. Amprologix is also in the early stages of
developing a novel antibiotic for prevention and treatment of Clostridioides
difficile (C. difficile) infections.

 

Frontier IP Chief Executive Officer Neil Crabb said: "The World Health
Organisation has identified antimicrobial resistant diseases as one of the top
10 threats to human health globally. I am therefore excited by the potential
for Amprologix's novel antibiotics in helping to fight this scourge. Research
results to date have been highly encouraging, and I am delighted by the
success of this funding round, which will play a vital role in taking
epidermicin NI01 through to human clinical trials."

 

 

 

 

 

Amprologix statement begins:

 

 

 

Amprologix raises £740,000 in pre-Series A funding round to accelerate
development of novel antibiotics

 

[20 October 2025] Amprologix, a company pioneering new families of
antibiotics, today announces that it has raised £740,000 through a pre-Series
A investment round to accelerate development of its novel antibiotics to
tackle antimicrobial-resistant diseases.

The funds will be used to complete pre-clinical development of its lead
candidate epidermicin NI01 to support Phase I human clinical trials for
therapy of wound infections. New research has shown that a daily dose of
epidermicin NI01 is as effective at treating wound infections, including those
caused by Methicillin-resistant Staphylococcus aureus (MRSA), as the current
standard of care.

Antimicrobial resistance is one of the top 10 threats to human health
globally, according to the World Health Organization (WHO). In a recent
report, the WHO said there had been a sharp rise in infections resistant to
antibiotics between 2018 and 2023, in some groups of pathogens. MRSA is one of
the most common causes of hospital and community acquired bloodstream
infections, according to the WHO and it is classed as a 'high-priority'
antibiotic resistant pathogen.

Amprologix, a spinout company of the University of Plymouth, was founded to
commercialise the pioneering research of Professor of Medical Microbiology
Mathew Upton. It is also in the early stages of developing a novel antibiotic
for Clostridioides difficile (C. difficile) infection. MRSA and C. difficile
both cause infections that can be difficult to treat and new therapies are
urgently needed.

The raised funds will enable the company to provide £300,000 of matched
funding to deliver the £1 million TOBRADERM R&D project. Supported by
Innovate UK's highly competitive Biomedical Catalyst programme, the project is
aimed at advancing epidermicin NI01 through late pre-clinical testing for
common skin and wound infections.

Investors include angel-investor network Plutus Investment Group LLP, another
institution and individual angel investors. Plutus Investment Venture Partner
Dr Rita Dobmeyer is to join the Amprologix board as a Non-Executive Director.
She is an expert in strategic clinical development. Global full-service
Contract Research Organisation InClin is to support pre-clinical and clinical
development work.

Amprologix is also positioning itself for a Series A funding round with the
intention of raising £5 million to support the first human clinical trials of
epidermicin NI01 in 2026, and the expansion of the portfolio of new drugs in
development.

Mohammed Jamal, Chief Executive Officer and Chairman of Plutus Investment
Group, said: "Plutus are delighted to be working with Amprologix to help
secure this important seed funding that will allow the company to achieve key
preclinical milestones and we're looking forward to helping with a subsequent
series-A round."

Professor Mat Upton, Amprologix Chief Scientific Officer and Professor of
Medical Microbiology at the University of Plymouth, said: "I am extremely
excited about the work that we will be able to carry out in the coming months
with the recently secured investment. This will strengthen the case for
development of epidermicin NI01 into a new therapy for skin infections that
are a cause of pain and suffering for thousands of people in the UK every day.

"We urgently need new therapies for these and other infections, some of which
are life-threatening, and epidermicin has the potential to meet this need.

"Investment into this field is essential if we are going to make progress
addressing the rise of drug-resistant infections, which threaten modern
medical care. The support provided by our new investors is vital if we are to
be successful in these efforts."

 

 

Amprologix Statement ends

 

 

ENQUIRIES

     Frontier IP Group Plc                                                   T: 020 7332 2338
     Neil Crabb, Chief Executive                                             neil@frontierip.co.uk (mailto:neil@frontierip.co.uk)

     Andrew Johnson, Communications and investor relations                   M: 07464 546 025

     andrew.johnson@frontierip.co.uk

     Company website: www.frontierip.co.uk (http://www.frontierip.co.uk/)
     Allenby Capital Limited (Nominated Adviser)                             T: 0203 328 5656
     Nick Athanas / Dan Dearden-Williams

ABOUT FRONTIER IP

Frontier IP unites science, finance and industry by identifying strong
intellectual property and accelerating its development through a range of
commercialisation services. A critical part of the Group's work is involving
relevant industry partners at an early stage of development to ensure
technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence
income by taking an active involvement in spin-out companies, including
support for fund raising and collaboration with relevant industry partners at
an early stage of development.

About Reach announcements

This is a Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies
to distribute media only / non-regulatory news releases into the public
domain. Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be disseminated
as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQDLFFEBLEFBF



            Copyright 2019 Regulatory News Service, all rights reserved